Ratings biote Corp.

Equities

Real-time Estimate Cboe BZX Other stock markets 07:14:07 10/05/2024 pm IST			5-day change	1st Jan Change
6.22 ^USD	-0.48%		+8.13%	+26.52%

07/05	Earnings Flash (BTMD) BIOTE Reports Q1 Revenue $46.8M, vs. Street Est of $45.7M	MT
07/05	Transcript : Biote Corp., Q1 2024 Earnings Call, May 07, 2024

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2026.
The company's profit outlook over the next few years is a strong asset.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.

With a 2024 P/E ratio at 31.25 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BIOTE CORP.	+26.52%	216M		-
CENGAGE LEARNING HOLDINGS II, INC.	+35.90%	828M	-	D
NIIT LIMITED	-13.84%	160M		C
DAEKYO CO., LTD.	+0.77%	145M		-
FLOWSPARKS N.V.	0.00%	53.41M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality